NEW YORK (GenomeWeb) — NanoView Biosciences said today that it has closed a $10 million Series B round of financing.
The round was led by Northpond Ventures and included existing investors Sands Capital Ventures and PBM Capital Group.
Boston-based NanoView said it will use the funding to complete development of its ExoView system for the characterization of exosomes and other extracellular vesicles, as well as prepare for the product's commercial launch in early 2019.
The ExoView technology uses single particle interferometric reflective imaging sensing to detect the enhanced scattering of extracellular vesicles bound to a microarray surface via antibody/antigen interaction. The platform is capable of measuring the concentration and size of extracellular vesicles as small as 40 nanometers and requires no sample labeling, according to NanoView.
Last month, NanoView won a $750,000 grant from the National Science Foundation to help develop the system.